1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. Colorado >
  6. Biodesix Acquires Integrated Diagnostics

M&A Deal Summary

Biodesix Acquires Integrated Diagnostics

On July 9, 2018, Biodesix acquired medical products company Integrated Diagnostics

Acquisition Highlights
  • This is Biodesix’s 1st transaction in the Medical Products sector.
  • This is Biodesix’s 1st transaction in the United States.
  • This is Biodesix’s 1st transaction in Colorado.

M&A Deal Summary
Date 2018-07-09
Target Integrated Diagnostics
Sector Medical Products
Buyer(s) Biodesix
Deal Type Add-on Acquisition

Target

Integrated Diagnostics

Boulder, Colorado, United States
Integrated Diagnostics, Inc. is a provider of XL2 test, and an oncology product, which offers a noninvasive means of ruling out cancer for patients with suspicious lung nodules. Integrated Diagnostics is based in Boulder, Colorado.

Search 214,238 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Biodesix

Louisville, Colorado, United States
Category Company
Founded 2005
Sector Life Science
Employees273
Revenue 71M USD (2024)
DESCRIPTION

Biodesix is a molecular diagnostics company advancing the development of innovative, multi-omic blood tests in oncology to enable precision medicine. Biodesix discovers, develops, and commercializes multivariate protein and genomic liquid biopsy tests, including the GeneStrat and VeriStrat tests, that deliver results within 72 hours. Biodesix was founded in 2005 and is based in Boulder, Colorado.

DEAL STATS #
Overall 1 of 1
Sector: Medical Products M&A 1 of 1
Type: Add-on Acquisition M&A Deals 1 of 1
State: Colorado M&A 1 of 1
Country: United States M&A 1 of 1
Year: 2018 M&A 1 of 1
Mergr

Solution for

Product

Company

Legal